Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 13


Functionalized NaA nanozeolites labeled with 224,225Ra for targeted alpha therapy.

Piotrowska A, Leszczuk E, Bruchertseifer F, Morgenstern A, Bilewicz A.

J Nanopart Res. 2013;15:2082. Epub 2013 Oct 31.


High efficiency diffusion molecular retention tumor targeting.

Guo Y, Yuan H, Cho H, Kuruppu D, Jokivarsi K, Agarwal A, Shah K, Josephson L.

PLoS One. 2013;8(3):e58290. doi: 10.1371/journal.pone.0058290. Epub 2013 Mar 11.


Human epidermal growth factor receptor 2 protein expression between primary breast cancer and paired asynchronous local-regional recurrences.

Xiang J, Pan X, Xu J, Fu X, Wu D, Zhang Y, Shen L, Wei Q.

Exp Ther Med. 2011 Nov;2(6):1187-1191. Epub 2011 Aug 12.


Chemoradionuclide therapy with 186re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response.

Soundararajan A, Bao A, Phillips WT, McManus LM, Goins BA.

Cancer Biother Radiopharm. 2011 Oct;26(5):603-14. doi: 10.1089/cbr.2010.0948. Epub 2011 Aug 11.


Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy.

Ting G, Chang CH, Wang HE, Lee TW.

J Biomed Biotechnol. 2010;2010. pii: 953537. doi: 10.1155/2010/953537. Epub 2010 Aug 3. Review.


Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.

Zhu X, Palmer MR, Makrigiorgos GM, Kassis AI.

Med Phys. 2010 Jun;37(6):2974-84.


EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.

Shen L, Shui Y, Wang X, Sheng L, Yang Z, Xue D, Wei Q.

BMC Cancer. 2008 Aug 12;8:232. doi: 10.1186/1471-2407-8-232.


Targeted radionuclide therapy.

Williams LE, DeNardo GL, Meredith RF.

Med Phys. 2008 Jul;35(7):3062-8.


Targeted radiotherapy: microgray doses and the bystander effect.

Mairs RJ, Fullerton NE, Zalutsky MR, Boyd M.

Dose Response. 2007 Apr 20;5(3):204-13. doi: 10.2203/dose-response.07-002.Mairs.


Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Boswell CA, Brechbiel MW.

Nucl Med Biol. 2007 Oct;34(7):757-78. Epub 2007 Jun 8. Review.


Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.

Carlsson J, Eriksson V, Stenerlöw B, Lundqvist H.

Eur J Nucl Med Mol Imaging. 2006 Oct;33(10):1185-95. Epub 2006 May 23.


HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review.

Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C.

Br J Cancer. 2004 Jun 14;90(12):2344-8. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk